These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27425582)

  • 1. Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance.
    Mason MD; Moore R; Jones G; Lewis G; Donovan JL; Neal DE; Hamdy FC; Lane JA; Staffurth JN;
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e92-e100. PubMed ID: 27425582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer.
    Sydes MR; Stephens RJ; Moore AR; Aird EG; Bidmead AM; Fallowfield LJ; Graham J; Griffiths S; Mayles WP; McGuire A; Stanley S; Warrington AP; Dearnaley DP;
    Radiother Oncol; 2004 Aug; 72(2):199-211. PubMed ID: 15297138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.
    Naismith O; Mayles H; Bidmead M; Clark CH; Gulliford S; Hassan S; Khoo V; Roberts K; South C; Hall E; Dearnaley D;
    Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):611-620. PubMed ID: 31201110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397).
    Mayles WP; Moore AR; Aird EG; Bidmead AM; Dearnaley DP; Griffiths SE; Warrington AP;
    Radiother Oncol; 2004 Nov; 73(2):199-207. PubMed ID: 15622611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991.
    Ataman F; Poortmans P; Davis JB; Bernier J; Giraud JY; Kouloulias VE; Pierart M; Bolla M
    Eur J Cancer; 2004 Nov; 40(16):2411-6. PubMed ID: 15519513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial.
    Kearvell R; Haworth A; Ebert MA; Murray J; Hooton B; Richardson S; Joseph DJ; Lamb D; Spry NA; Duchesne G; Denham JW
    J Med Imaging Radiat Oncol; 2013 Apr; 57(2):247-57. PubMed ID: 23551788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10.
    Sassowsky M; Gut P; Hölscher T; Hildebrandt G; Müller AC; Najafi Y; Kohler G; Kranzbühler H; Guckenberger M; Zwahlen DR; Azinwi NC; Plasswilm L; Takacs I; Reuter C; Sumila M; Manser P; Ost P; Böhmer D; Pilop C; Aebersold DM; Ghadjar P
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):534-41. PubMed ID: 23972722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy.
    Wills L; Maggs R; Lewis G; Jones G; Nixon L; Staffurth J; Crosby T;
    Radiat Oncol; 2017 Nov; 12(1):179. PubMed ID: 29141663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial.
    Seddon B; Bidmead M; Wilson J; Khoo V; Dearnaley D
    Radiother Oncol; 2000 Jul; 56(1):73-83. PubMed ID: 10869758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review.
    Matzinger O; Poortmans P; Giraud JY; Maingon P; Budiharto T; van den Bergh AC; Davis JB; Musat E; Ataman F; Huyskens DP; Gulyban A; Bolla M;
    Radiother Oncol; 2009 Mar; 90(3):285-90. PubMed ID: 19038468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A versatile phantom for quality assurance in the UK Medical Research Council (MRC) RT01 trial (ISRCTN47772397) in conformal radiotherapy for prostate cancer.
    Moore AR; Warrington AP; Aird EG; Bidmead AM; Dearnaley DP
    Radiother Oncol; 2006 Jul; 80(1):82-5. PubMed ID: 16828908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
    Malone S; Croke J; Roustan-Delatour N; Belanger E; Avruch L; Malone C; Morash C; Kayser C; Underhill K; Li Y; Malone K; Nyiri B; Spaans J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):725-32. PubMed ID: 22444999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial experience with quality assurance of multi-institutional 3D radiotherapy clinical trials. A brief report.
    Purdy JA; Harms WB; Michalski J; Bosch WR
    Strahlenther Onkol; 1998 Oct; 174 Suppl 2():40-2. PubMed ID: 9810337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survey of UK breast radiotherapy techniques: background prior to the introduction of the quality assurance programme for the START (standardisation of radiotherapy) trial in breast cancer.
    Winfield E; Deighton A; Venables K; Hoskin PJ; Aird EG
    Clin Oncol (R Coll Radiol); 2002 Aug; 14(4):267-71. PubMed ID: 12206636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy trial quality assurance processes: a systematic review.
    Brooks C; Miles E; Hoskin PJ
    Lancet Oncol; 2024 Mar; 25(3):e104-e113. PubMed ID: 38423056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do differences in target volume definition in prostate cancer lead to clinically relevant differences in normal tissue toxicity?
    Livsey JE; Wylie JP; Swindell R; Khoo VS; Cowan RA; Logue JP
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1076-81. PubMed ID: 15519777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simplified intensity-modulated arc therapy for dose escalated prostate cancer radiotherapy.
    Bauman G; Gete E; Chen JZ; Wong E
    Med Dosim; 2004; 29(1):18-25. PubMed ID: 15023389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and physical quality assurance for intensity modulated radiotherapy of prostate cancer.
    Boehmer D; Bohsung J; Eichwurzel I; Moys A; Budach V
    Radiother Oncol; 2004 Jun; 71(3):319-25. PubMed ID: 15172148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Quality criteria in radiotherapy for head and neck cancers under the aegis of Head and Neck Intergroup].
    Tao Y; Vintonenko N; Garcia R; Marchesi V; Tomsej M; Bardet E; Bourhis J
    Bull Cancer; 2014 May; 101(5):481-5. PubMed ID: 24886899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-escalated 3D conformal radiotherapy in prostate cancer.
    Malone S
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):663-8. PubMed ID: 15270669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.